Media coverage about Nektar Therapeutics (NASDAQ:NKTR) has trended somewhat positive recently, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Nektar Therapeutics earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.7775604448279 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news articles that may have impacted Accern’s analysis:
- Nektar Therapeutics (NKTR) COO John Nicholson Sells 15,910 Shares (americanbankingnews.com)
- Nektar Therapeutics’ stock rockets toward near 17-year high after upbeat trial data – MarketWatch (marketwatch.com)
- This Biotech Just Neared A 17-Year High On Strong Cancer Regimen – Investor’s Business Daily (investors.com)
- New Research Collaboration Between BioXcel Therapeutics and Nektar to Evaluate BXCL701 in Combination with NKTR-214 in Multiple Oncology Indications (globenewswire.com)
- Nektar Therapeutics makes 15-year highs after cancer treatment data for NKTR-214 with Opdivo (NKTR) (briefing.com)
A number of equities research analysts recently weighed in on NKTR shares. Canaccord Genuity Group Inc. raised their price target on Nektar Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a report on Wednesday. Mizuho raised their price target on Nektar Therapeutics from $30.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday. Roth Capital set a $45.00 price target on Nektar Therapeutics and gave the company a “buy” rating in a report on Monday. J P Morgan Chase & Co reaffirmed a “buy” rating and set a $44.00 price target on shares of Nektar Therapeutics in a report on Monday. Finally, Canaccord Genuity started coverage on Nektar Therapeutics in a report on Thursday, November 9th. They set a “buy” rating and a $35.00 price target for the company. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $34.33.
Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.21 by $0.16. The company had revenue of $152.90 million during the quarter, compared to analysts’ expectations of $126.50 million. Nektar Therapeutics had a negative return on equity of 190.68% and a negative net margin of 42.08%. The business’s revenue for the quarter was up 321.2% on a year-over-year basis. During the same period last year, the firm earned ($0.32) EPS. equities research analysts expect that Nektar Therapeutics will post -0.78 EPS for the current year.
In related news, CEO Howard W. Robin sold 83,333 shares of Nektar Therapeutics stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $21.54, for a total transaction of $1,794,992.82. Following the completion of the sale, the chief executive officer now directly owns 235,837 shares of the company’s stock, valued at $5,079,928.98. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO John Nicholson sold 15,910 shares of Nektar Therapeutics stock in a transaction on Monday, November 13th. The stock was sold at an average price of $37.78, for a total value of $601,079.80. Following the sale, the chief operating officer now directly owns 249,066 shares of the company’s stock, valued at $9,409,713.48. The disclosure for this sale can be found here. Insiders sold a total of 941,427 shares of company stock valued at $24,663,626 over the last three months. Insiders own 6.10% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Nektar Therapeutics (NKTR) Receiving Somewhat Positive Press Coverage, Study Shows” was first published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.themarketsdaily.com/2017/11/16/nektar-therapeutics-nktr-receiving-somewhat-positive-press-coverage-study-shows.html.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.